Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

PURPOSE: Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of patients. Clinically available tools to optimize use of ICIs and understand the molecular determinants of response are needed....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Rizvi, Hira, Sanchez-Vega, Francisco, La, Konnor, Chatila, Walid, Jonsson, Philip, Halpenny, Darragh, Plodkowski, Andrew, Long, Niamh, Sauter, Jennifer L., Rekhtman, Natasha, Hollmann, Travis, Schalper, Kurt A., Gainor, Justin F., Shen, Ronglai, Ni, Ai, Arbour, Kathryn C., Merghoub, Taha, Wolchok, Jedd, Snyder, Alexandra, Chaft, Jamie E., Kris, Mark G., Rudin, Charles M., Socci, Nicholas D., Berger, Michael F., Taylor, Barry S., Zehir, Ahmet, Solit, David B., Arcila, Maria E., Ladanyi, Marc, Riely, Gregory J., Schultz, Nikolaus, Hellmann, Matthew D.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2018
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6075848/
https://ncbi.nlm.nih.gov/pubmed/29337640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.3384
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars